To evaluate whether this data-driven cutoff may be generalisable to other cohorts and thus a feasible clinical strategy, we assessed the distribution of ESR1 and PGR expression in an independent cohort of metastatic breast cancer that includes GEX data from primary tumours and distant metastases. The gene discussed is PGR; the disease is breast carcinoma.